Zinman Jon 4

What Happened

• Jon Zinman, a director of Keenova Therapeutics plc, was granted 4,406 restricted stock units (transaction code A) on July 15, 2026. The RSUs are recorded at $0.00 per share (aggregate reported value $0) as a derivative award rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (appears timely under Form 4 rules).
• Award: 4,406 RSUs; reported price: $0.00; aggregate reported value: $0.
• Shares owned after transaction: not disclosed in the filing.
• Footnotes: (F1) Each RSU will be settled in one ordinary share upon vesting. (F2) Vesting occurs on the earlier of (i) the first anniversary of the grant date or (ii) the date of the issuer’s next annual general meeting of shareholders.
• Remarks: The filing also serves as the issuer notice required under Part V of the Companies Act 2014.

Context

• RSUs are a form of equity compensation (a derivative grant). They do not represent immediate cash proceeds; value to the holder depends on Keenova’s share price at settlement and satisfying vesting conditions. Grants to directors are common and should be interpreted as compensation, not a direct buy or sell signal.